The study was evaluated the impact of Consciousness Energy Healing Treatment/Blessing (the Trivedi Effect®) on test formulation in rats under the influence of vitamin D3 deficiency diet (VDD). The following mechanistic biomarkers were estimated such as vitamin D receptor (VDR), telomerase, and citrate synthase enzymes. The test formulation’s ingredient was divided into two parts; one part was defined as untreated test formulation, while the other parts and the animals provided Biofield Energy Healing/Blessing Treatment by Mr. Mahendra Kumar Trivedi. The expression of VDR in liver was significant increased by 74.91%, 100.66%, and 64.25% in the G5 (VDD + Biofield Energy Treated test formulation), G6 (VDD + Biofield Energy Treatment per se to animals from day -15), and G7 (VDD + Biofield Energy Treated test formulation from day -15) groups, respectively as compared with the disease control (G2) group. Similarly, the expression of VDR in adipose tissue was significant increased by 268.6% (p≤0.001), 163.13% (p≤0.001), 92.42%, and 63.25% in G5, G6, G7, and G9 groups, respectively, than G4. However, the level of liver telomerase was reported to be increased by 59.09% (p≤0.001), 68.18% (p≤0.001), and 68.18% (p≤0.001) in the G6, G7, and G8, respectively as compared to the G4. Similarly, the telomerase level in the thigh muscle was significant increased by 15.79% in the G7 group as compared with the G4 group. Besides, the level of citrate synthase was significantly increased by 5.89% in the G8 group as compared to the G2 group. Altogether, the Biofield Treated/Blessed test formulation and Biofield Treatment per se to the animals could be an effective approach to improve the functioning of VDR (liver and adipose tissue), telomerase enzyme (liver and thigh muscle), and mitochondrial activity in terms of citrate synthase (substrate of kreb’s cycle). Therefore, the findings could be used against bone-related disorders (osteoporosis, fracture, scoliosis, and bone cancer), deficiency of vitamin D3, and mitochondrial dysfunction in associate with age-related and neurodegeneration disorders such as Alzheimer’s disease, dementias, brain cancer, epilepsy and Parkinson’s. The data showed a significant reduction of disease progression and all other disease-related complications/symptoms in the preventive treatment groups viz. G6, G7, G8, and G9.
